Exclusive-Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say [Yahoo! Finance]
Inhibrx Biosciences, Inc. (INBX)
Company Research
Source: Yahoo! Finance
KGaA and Japan's Ono Pharmaceutical for an experimental cancer treatment that could be valued at more than $8 billion, people familiar with the matter said. The San ?Diego-based biotech is exploring the joint spin-off of the drug, INBRX-106, and a second experimental cancer treatment, which could have a combined value ?of more than $9 billion if clinical trials succeed, the people said. Interest is concentrated on INBRX-106, which is being tested alone and in combination with Merck's Keytruda. Inhibrx has said it believes its ?drug can boost the efficacy of New Jersey-based Merck's more than $30-billion-a-year immunotherapy, the world's top-selling prescription medicine. Keytruda, which is approved to treat a wide variety of cancers, accounted for almost half of Merck's global sales in 2025. Talks are in early stages and any deal would likely be several months away, with valuation hinging on upcoming trial results, the people said, speaking on condition of anonymity because th
Show less
Read more
Impact Snapshot
Event Time:
INBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INBX alerts
High impacting Inhibrx Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
INBX
News
- T-Mobile reportedly in merger talks, Adobe's $25B stock buyback [Yahoo! Finance Canada]Yahoo! Finance Canada
- Inhibrx cancer drug reportedly drawing interest of Merck and rivals [Seeking Alpha]Seeking Alpha
- Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer [TheStreet.com]TheStreet.com
- Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal CancerPR Newswire
- Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
INBX
Earnings
- 8/13/25 - Beat
INBX
Sec Filings
- 4/21/26 - Form 8-K
- 3/19/26 - Form 10-K
- 3/19/26 - Form 8-K
- INBX's page on the SEC website